These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7284263)

  • 21. Anthralin: chemical instability and glucose-6-phosphate dehydrogenase inhibition.
    Cavey D; Caron JC; Shroot B
    J Pharm Sci; 1982 Sep; 71(9):980-3. PubMed ID: 7131282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
    Van Duuren BL; Segal A; Tseng SS; Rusch GM; Loewengart G; Maté U; Roth D; Smith A; Melchionne S; Seidman I
    J Med Chem; 1978 Jan; 21(1):26-31. PubMed ID: 619147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes.
    Reichert U; Jacques Y; Grangeret M; Schmidt R
    J Invest Dermatol; 1985 Feb; 84(2):130-4. PubMed ID: 2578530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of soybean lipoxygenase-1 by 10-butyryl substituted 1,8-dihydroxy-9-anthrone (butantrone).
    Laakso S; Römer L; Mustakallio KK
    Med Biol; 1986; 64(1):43-5. PubMed ID: 3088340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of an antipsoriatic agent, dithranol, on mitochondrial and nuclear functions in yeast cells.
    Zetterberg G
    Hereditas; 1977; 86(2):191-204. PubMed ID: 334708
    [No Abstract]   [Full Text] [Related]  

  • 26. A microspectrofluorometric study of the effect of anthralin, an antipsoriatic drug, on cellular structures and metabolism.
    Kohen E; Kohen C; Morliere P; Santus R; Reyftmann JP; Dubertret L; Hirschberg JG; Coulomb B
    Cell Biochem Funct; 1986 Jul; 4(3):157-68. PubMed ID: 3731395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elimination of metabolic cooperation is associated with the tumor promoters, oleic acid and anthralin.
    Trosko JE; Jone C; Aylsworth C; Tsushimoto G
    Carcinogenesis; 1982; 3(9):1101-3. PubMed ID: 7139869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of epidermal proliferation by ultraviolet light, coal tar and anthralin.
    Walter JF; Stoughton RB; DeQuoy PR
    Br J Dermatol; 1978 Jul; 99(1):89-96. PubMed ID: 678469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study on the mode of action of dithranol: increased lipid peroxidation and enzyme inhibition].
    Diezel W; Meffert H; Sönnichsen N
    Dermatologica; 1975; 150(3):154-62. PubMed ID: 125665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anthralin: chemical instability and glucose-6-phosphate dehydrogenase inhibition.
    Cavey D; Caron JC; Shroot B
    Br J Dermatol; 1981 Aug; 105 Suppl 20():15-9. PubMed ID: 7284258
    [No Abstract]   [Full Text] [Related]  

  • 31. Langerhans' cells in patients with psoriasis: effect of treatment with PUVA, PUVA bath, etretinate and anthralin.
    Czernielewski J; Juhlin L; Shroot S; Brun P
    Acta Derm Venereol; 1985; 65(2):97-101. PubMed ID: 2408430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time course and intensity of anthralin inflammation on involved and uninvolved psoriatic skin.
    Paramsothy Y; Lawrence CM
    Br J Dermatol; 1987 Apr; 116(4):517-9. PubMed ID: 3580286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skin toxicity and cellular metabolism: in vitro models.
    Reichert U
    Br J Dermatol; 1986 Aug; 115 Suppl 31():108-16. PubMed ID: 3741793
    [No Abstract]   [Full Text] [Related]  

  • 34. [Side effects of anthralin and its 2 main impurities on healthy skin].
    Puschmann M; Schmersahl P
    Z Hautkr; 1983 Mar; 58(6):410-6. PubMed ID: 6857758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inactivation of mouse epidermal 12-lipoxygenase by anthralin--implications for the role of oxygen radicals.
    Müller K; Gawlik I
    Biochem Pharmacol; 1996 May; 51(9):1173-9. PubMed ID: 8645340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-function relationship of new anthralin derivatives assayed for growth inhibition and cytotoxicity in human keratinocyte cultures.
    Bonnekoh B; Tanzer H; Seidel M; Geisel J; Merk HF; Mahrle G; Wiegrebe W
    Arch Pharm (Weinheim); 1991 Nov; 324(11):899-906. PubMed ID: 1804068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of anthralin inflammation. 2. Effect of pretreatment with glucocorticoids, anthralin and removal of stratum corneum.
    Lawrence CM; Shuster S
    Br J Dermatol; 1985 Jul; 113(1):117-22. PubMed ID: 4015968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irritation and staining by dithranol (anthralin) and related compounds. V. Short-contact and tape-stripping experiments with dithranol and butantrone.
    Göransson AM; Kolari PJ; Mustakallio KK
    Acta Derm Venereol; 1984; 64(2):134-9. PubMed ID: 6203301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antioxidant and prooxidant effects of the antipsoriatic compound anthralin in skin and subcellular fractions.
    Fuchs J; Nitschmann W; Packer L
    Adv Exp Med Biol; 1990; 264():537-41. PubMed ID: 2244537
    [No Abstract]   [Full Text] [Related]  

  • 40. Current concepts in the mode of action of anthralin in the treatment of psoriasis.
    Br J Dermatol; 1981 Aug; 105 Suppl 20():1-114. PubMed ID: 7284252
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.